Meunier et al. reported 48 cases of ICI-related cholangitis, 41 of which were associated with anti-PD-1 inhibitors (Liu et al., 2021)——a finding supported by our real-world data, which demonstrated significantly stronger immune-mediated cholangitis signals for nivolumab and pembrolizumab compared to anti-PD-L1 agents (e.g., atezolizumab). Here, CD274 is linked to cholangitis.